| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
PAPER |
1 Centro di Riferimento Regionale Sclerosi Multipla & Laboratorio di Neurobiologia Clinica, Divisione Universitaria di Neurologia, Azienda Ospedaliera S Luigi, Università di Torino, Orbassano, Italy
2 Dipartimento Scienze Neurologiche; Università Federico II, Napoli, Italy
Correspondence to:
Correspondence to:
Dr A Bertolotto, Centro Sclerosi Multipla & Laboratorio di Neurobiologia Clinica, Divisione Universitaria di Neurologia, Azienda Ospedaliera S Luigi di Orbassano, Università di Torino–Regione Piemonte, Regione Gonzole 10, 10043, Orbassano, Italy;
nsglb{at}tin.it
Methods: Sera were tested from 125 patients with relapsing-remitting MS. Patients were treated with IFNß-1b (Betaferon, n = 29) 8 MIU subcutaneously every other day, IFNß-1a (Avonex, n = 44) 30 µg intramuscularly once weekly, or IFNß-1a (Rebif, n = 36) 22 µg subcutaneously three times weekly for 6 to 18 months. An additional 16 patients were treated with Rebif 22 µg intramuscularly once or twice weekly. NABs were assessed using the cytopathic effect assay before treatment and every three months during treatment. Patients with two or more consecutive positive samples were considered to be persistent NAB positive (NAB+).
Results: At baseline, no patients were NAB+. NABs developed during the first three months of treatment and continued to develop until month 18. Over 18 months of treatment, the risk of being persistent NAB+ was 31% for Betaferon, 15% for Rebif, and 2% for Avonex (Betaferon versus Avonex, p = 0.001; Betaferon versus Rebif, p = 0.19; Rebif versus Avonex, p = 0.04). In all patients with one or more NAB+ samples, the risk of becoming NAB+ was 38% for Betaferon, 18% for Rebif, and 7% for Avonex (Betaferon versus Avonex, p = 0.0007; Betaferon versus Rebif, p = 0.10; Rebif versus Avonex, p = 0.07). At month 18, the prevalence of persistent NAB+ patients was 31.6% for Betaferon, 18.7% for Rebif, and 4% for Avonex. Numbers of NAB+ patients observed were similar with intramuscular Rebif and with subcutaneous Rebif.
Conclusion: The three IFNß preparations have different degrees of immunogenicity, with Betaferon producing the highest incidence of NABs and Avonex the lowest. These differences should be considered by neurologists when selecting treatment for their patients with MS because NABs can reduce both bioavailability and clinical efficacy of IFNß.
Keywords: interferon beta; multiple sclerosis; neutralising antibodies
Abbreviations: CPE, cytopathic effect; EDSS, expanded disability status scale; IFNß, interferon beta; LU, laboratory units; MS, multiple sclerosis; NAB, neutralising antibody; PRISMS, prevention of relapses and disability by interferon ß-1a subcutaneously in multiple sclerosis; WHO, World Health Organization
This article has been cited by other articles:
|
|
 |
|
  N. Garg, B. Weinstock-Guttman, K. Bhasi, J. Locke, and M. Ramanathan An association between autoreactive antibodies and anti-interferon-{beta} antibodies in multiple sclerosis Multiple Sclerosis, August 1, 2007; 13(7): 895 - 899. [Abstract] [PDF]
|
|
|
|
|
|
R. A Farrell and G. Giovannoni Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis Multiple Sclerosis, June 1, 2007; 13(5): 567 - 577. [Abstract] [PDF]
|
|
|
|
|
|
R. Zivadinov, L. Locatelli, D. Cookfair, B. Srinivasaraghavan, A. Bertolotto, M. Ukmar, A. Bratina, C. Maggiore, A. Bosco, A. Grop, et al. I nterferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy Multiple Sclerosis, May 1, 2007; 13(4): 490 - 501. [Abstract] [PDF]
|
|
|
|
|
|
A.T. Reder Neutralizing antibodies in multiple sclerosis: a complex impact on interferon responses, magnetic resonance imaging findings and clinical outcomes Multiple Sclerosis, May 1, 2007; 13(1_suppl): 53 - 62. [Abstract] [PDF]
|
|
|
|
|
|
C Gneiss, P Tripp, F Reichartseder, R Egg, R Ehling, A Lutterotti, M Khalil, B Kuenz, I Mayringer, M Reindl, et al. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients Multiple Sclerosis, November 1, 2006; 12(6): 731 - 737. [Abstract] [PDF]
|
|
|
|
|
|
B. Petersen, K. Bendtzen, N. Koch-Henriksen, M. Ravnborg, C. Ross, P. S. Sorensen, and The Danish Multiple Sclerosis Group Persistence of neutralizing antibodies after discontinuation of IFN{beta} therapy in patients with relapsing-remitting multiple sclerosis Multiple Sclerosis, June 1, 2006; 12(3): 247 - 252. [Abstract] [PDF]
|
|
|
|
|
|
R. M Herndon, R. A Rudick, F. E Munschauer III, M. K Mass, A. M Salazar, M. E Coats, R. Labutta, J. R Richert, S. L Cohan, C. Genain, et al. Eight-year immunogenicity and safety of interferon beta-1a-Avonex(R)treatment in patients with multiple sclerosis Multiple Sclerosis, August 1, 2005; 11(4): 409 - 419. [Abstract] [PDF]
|
|
|
|
 |
|
 G. S. Francis, G. P.A. Rice, J. C. Alsop, and for the PRISMS (Prevention of Relapses and Disabil Interferon {beta}-1a in MS: Results following development of neutralizing antibodies in PRISMS Neurology, July 12, 2005; 65(1): 48 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Sorensen, N. Koch-Henriksen, C. Ross, K. M. Clemmesen, K. Bendtzen, and the Danish Multiple Sclerosis Study Group Appearance and disappearance of neutralizing antibodies during interferon-beta therapy Neurology, July 12, 2005; 65(1): 33 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. H. Stuart, S. Cohan, J. R. Richert, and A. Achiron Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S19 - S27. [Abstract] [Full Text]
|
|
|
|
|
|
W. H. Stuart and P. Vermersch Concomitant therapy for multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S28 - S34. [Abstract] [Full Text]
|
|
|
|
|
|
T. K. Vartanian, S. S. Zamvil, E. Fox, and P. S. Sorensen Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S42 - S49. [Abstract] [Full Text]
|
|
|
|
|
|
C Gneiss, M Reindl, A Lutterotti, R Ehling, R Egg, M Khalil, T Berger, and F Deisenhammer Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity Multiple Sclerosis, October 1, 2004; 10(5): 507 - 510. [Abstract] [PDF]
|
|
|
|
|
|
T L Vollmer, J T Phillips, A D Goodman, M A Agius, M A Libonati, J L Giacchino, and J S Grundy An open-label safety and drug interaction study of natalizumab (AntegrenTM) in combination with interferon-beta (Avonex(R)) in patients with multiple sclerosis Multiple Sclerosis, October 1, 2004; 10(5): 511 - 520. [Abstract] [PDF]
|
|
|
|
 |
|
 A Bertolotto, A Sala, S Malucchi, F Marnetto, M Caldano, A Di Sapio, M Capobianco, and F Gilli Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies J. Neurol. Neurosurg. Psychiatry, September 1, 2004; 75(9): 1294 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Malucchi, A. Sala, F. Gilli, R. Bottero, A. Di Sapio, M. Capobianco, and A. Bertolotto Neutralizing antibodies reduce the efficacy of {beta}IFN during treatment of multiple sclerosis Neurology, June 8, 2004; 62(11): 2031 - 2037. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Gilli, A. Bertolotto, A. Sala, F. Hoffmann, M. Capobianco, S. Malucchi, T. Glass, L. Kappos, R. L.P. Lindberg, and D. Leppert Neutralizing antibodies against IFN-{beta} in multiple sclerosis: antagonization of IFN-{beta} mediated suppression of MMPs Brain, February 1, 2004; 127(2): 259 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Bendtzen Anti-IFN BAb and NAb antibodies: A minireview Neurology, November 11, 2003; 61(90095): S6 - 10. [Full Text]
|
|
|
|
|
|
G. Giovannoni Strategies to treat and prevent the development of neutralizing anti-interferon-{beta} antibodies Neurology, November 11, 2003; 61(90095): S13 - 17. [Abstract] [Full Text]
|
|
|
|
|
|
M. Trojano, M. Liguori, D. Paolicelli, G. B. Zimatore, F. De Robertis, C. Avolio, F. Giuliani, A. Fuiani, P. Livrea, and Southern Italy MS Group Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy Multiple Sclerosis, October 1, 2003; 9(5): 451 - 457. [Abstract] [PDF]
|
|
|
|
|
|
A. Bertolotto, F. Gilli, A. Sala, M. Capobianco, S. Malucchi, E. Milano, F. Melis, F. Marnetto, R. L.P. Lindberg, R. Bottero, et al. Persistent neutralizing antibodies abolish the interferon {beta} bioavailability in MS patients Neurology, February 25, 2003; 60(4): 634 - 639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Giovannoni, F E Munschauer 3rd, and F Deisenhammer Neutralising antibodies to interferon beta during the treatment of multiple sclerosis J. Neurol. Neurosurg. Psychiatry, November 1, 2002; 73(5): 465 - 469. [Full Text] [PDF]
|
|
|
|
|
|
A J Coles Neutralising antibodies to the beta interferons J. Neurol. Neurosurg. Psychiatry, August 1, 2002; 73(2): 110 - 111. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
